Grifols, S.A. is a vertically integrated global biopharmaceutical company and a leading producer of plasma-derived medicines. The company operates through three primary business segments: Biopharma, Diagnostic, and Bio Supplies. The Biopharma segment is the core growth engine, generating the vast majority of the company's revenue (historically over 80%), and focuses on the research, development, and production of plasma-derived therapeutics such as immunoglobulins (IVIG and SCIG), albumin, clotting factors, and alpha-1 antitrypsin to treat rare, chronic, and life-threatening conditions. The Diagnostic segment provides clinical testing equipment, reagents, and transfusion medicine solutions for blood banks and hospitals. The Bio Supplies segment offers biological products for non-therapeutic use, including life-science research and clinical trials. Geographically, Grifols has a massive footprint, operating nearly 400 plasma donation centers globally, with a heavy concentration in the United States, which serves as its primary source of raw plasma and its largest commercial market. The company's competitive position is underpinned by its extensive proprietary plasma collection network and its specialized fractionation and purification manufacturing capabilities, making it one of the few dominant players in the highly consolidated global plasma therapeutics industry.
